QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor ty... Read more
Mineralys Therapeutics
3 followers
Ultima Genomics
6 followers
Obsidian Therapeutics
1 follower
Arc Institute
4 followers
Thermo Fisher Scientific
287 followers
Genentech
227 followers
Gilead Sciences
216 followers
Regeneron
184 followers
Biogen
167 followers
Vertex Pharmaceuticals
113 followers
Agilent Technologies
102 followers
Illumina
93 followers